CSIMarket


Oncocyte Corporation  (OCX)
Other Ticker:  
 


 

Oncocyte Corporation

OCX's Financial Statements and Analysis



Oncocyte Corporation increased third quarter of 2023 net loss per share of $-0.81 compare to net loss per share of $-0.08 recorded in the same quarter a year ago and improved compare to net loss per share of $-1.07 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -0.81 $  0 Mill
$-0.73     Unch.     +946.34 %



Oncocyte's Revenue rose by 946.34 % in third quarter of 2023 (Sep 30 2023) year on year, to $0 million and declined by -7.34 % sequentially.


Oncocyte is Expected to report next financial results on April 11, 2024.

More on OCX's Income Statement



Oncocyte's in thethird quarter of 2023 recorded net loss of $-6.687 million, an improvement compare to net loss of $-9.555 million in III. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-8.644 million realized in previous quarter.

More on OCX's Growth

Oncocyte Inventories
In Sep 30 2023 company's net cash and cash equivalents decreased by $-4 million, capital expenditures grew by -0.859-98.02%, to $0 millions compare to same quarter a year ago

More on OCX's Cash flow Statement


Oncocyte Corporation does not pay out common stock dividend.

In trailing twelve-month period Oncocyte Corporation payed $ 0.00 cash per share, on a free-cash flow basis .

Book value fell by -15.58 % sequentially to $0.00 per share, -0.03% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.00 per share from $ 0.00.

Company issued 166.00 million shares or 2.05 % in Sep 30 2023.
Interest Coverage Ratio was 5.68.

More on OCX's Dividends

 Market Capitalization (Millions) 24,603
 Shares Outstanding (Millions) 8,256
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 6
 Net Income (TTM) (Millions $) -77
 Cash Flow (TTM) (Millions $) -18
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Oncocyte Corporation does not pay out common stock dividend.

In trailing twelve-month period Oncocyte Corporation had negative $ 0.00 cash flow per share, on a free-cash flow basis .

Book value fell by -15.58 % sequentially to $0.00 per share, -0.03% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.00 per share from $ 0.00.

Company issued 166.00 million shares or 2.05 % in Sep 30 2023.
Interest Coverage Ratio was 5.68.

More on OCX's Balance Sheets

 Market Capitalization (Millions) 24,603
 Shares Outstanding (Millions) 8,256
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 6
 Net Income (TTM) (Millions $) -77
 Cash Flow (TTM) (Millions $) -18
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Oncocyte Corporation Earnings

Oncocyte Corporation's Revenue Surges in Q3 2023, but Profitability Remains Elusive



Oncocyte Corporation, a leading player in the In Vitro and In Vivo Diagnostic Substances industry, recently released its financial results for the third quarter of 2023. Despite reporting a significant increase in revenue compared to the same period last year, the company witnessed a widening of its losses. This article will outline the key facts from Oncocyte Corporation's financial results and provide context to better understand the company's performance in the industry.
Revenue Growth and Comparisons:
Oncocyte Corporation announced an impressive year-on-year revenue advancement of 946.341% in the third quarter of 2023, reaching $0.43 million. This growth significantly outperformed its i...

Oncocyte Corporation Stumbles as Revenues Plummet 57.562% in Q2 2023, Raising Investor Alarm



In the wake of the most recent fiscal period, Oncocyte Corporation has unveiled concerning financial results, reporting a drastic decline in revenue and a significant increase in net loss per share. While the rest of the In Vitro and In Vivo Diagnostic Substances sector saw positive growth, Oncocyte Corporation struggled to maintain its foothold. This article seeks to shed light on the implications of the company's performance and its contrasting market sentiment.
Revenues and Net Loss Per Share:
Oncocyte Corporation's revenues plummeted by an alarming 57.562% to a mere $0.46 million in the most recent fiscal period. This decrease is significant, especially when compared to the correspondin...


Date modified: 2023-11-30T13:29:11+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com